Issue Date | Title | Author(s) | Source | scopus | WOS | Fulltext/Archive link |
---|---|---|---|---|---|---|
2022 | IgE-neutralizing UB-221 mAb, distinct from omalizumab and ligelizumab, exhibits CD23-mediated IgE downregulation and relieves urticaria symptoms | Kuo, Be-Sheng; Li, Chao-Hung; Chen, Jiun-Bo; Shiung, Yu-Yu; CHIA-YU CHU ; Lee, Chih-Hung; Liu, Yaw-Jen; et al., | The Journal of clinical investigation | 19 | 18 |